Foresite Capital Management VI LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 12, 2025), Foresite Capital Management VI LLC reported 20 stock positions worth $177.9 million. Its top holding was CG Oncology (CGON) at 32.5% of the portfolio, followed by Centessa Pharmaceuticals (CNTA, 9.3%) and Akero Therapeutics (AKRO, 7.3%). Compared with Q1 2025, it opened 7 new positions, sold out of 1, added to 2 and reduced 6. The biggest buy was a new position in Rapt Therapeutics (RAPT) and the biggest sale an exit from Rapt Therapeutics.
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0002013341
- Portfolio Value
- $177.9M (Q2 2025)
- SEC Filing
- 0001104659-25-076821 ↗ filed Aug 12, 2025
Holdings Value
Holdings 20 stocks · $177.9M
| CGON CG Oncology Inc. | 32.47% | 2,221,474 | $57.8M | No change |
| CNTA Centessa Pharmaceuticals Ltd. | 9.26% | 1,253,379 | $16.5M | No change |
| AKRO Akero Therapeutics Inc. | 7.35% | 244,900 | $13.1M | Reduce -32.9% |
| ALMS Alumis Inc. | 7.16% | 4,247,670 | $12.7M | Add +1.1% |
| RAPT Rapt Therapeutics Inc. | 7.03% | 1,562,500 | $12.5M | New |
| BCAX Bicara Therapeutics Inc. | 4.96% | 949,260 | $8.8M | Reduce -0.1% |
| EWTX Edgewise Therapeutics Inc. | 4.31% | 585,000 | $7.7M | No change |
| HNGE Hinge Health Inc. Class A | 3.93% | 135,000 | $7.0M | New |
| CRVS Corvus Pharmaceuticals Inc. | 3.89% | 1,731,233 | $6.9M | Add +9.5% |
| KYMR Kymera Therapeutics Inc. | 3.59% | 146,332 | $6.4M | No change |
| VSTM Verastem Inc. | 2.98% | 1,276,520 | $5.3M | New |
| XENE Xenon Pharmaceuticals Inc. | 2.82% | 160,000 | $5.0M | New |
| CGEM Cullinan Therapeutics Inc. | 2.51% | 594,025 | $4.5M | Reduce -6.4% |
| GPCR Structure Therapeutics Inc. | 2.45% | 210,000 | $4.4M | Reduce -50.0% |
| ALLO Allogene Therapeutics Inc. | 1.83% | 2,875,357 | $3.2M | Reduce -16.6% |
| IDYA Ideaya Biosciences Inc. | 1.71% | 144,468 | $3.0M | New |
| RNAM Avidity Biosciences Inc. | 0.64% | 40,000 | $1.1M | New |
| SYRE Spyre Therapeutics Inc. | 0.59% | 70,000 | $1.0M | New |
| CASIF Casi Pharmaceuticals Inc. | 0.52% | 787,121 | $929K | Reduce -40.8% |
| VRDN Viridian Therapeutics Inc. | 0.02% | 1,974 | $28K | No change |
Portfolio Sells Q1 2025 → Q2 2025
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −8.35 |
| BCAX Bicara Therapeutics Inc. | Reduce -0.1% | 4.96% | −1.82 |
| GPCR Structure Therapeutics Inc. | Reduce -50.0% | 2.45% | −1.53 |
| CASIF Casi Pharmaceuticals Inc. | Reduce -40.8% | 0.52% | −1.05 |
| ALLO Allogene Therapeutics Inc. | Reduce -16.6% | 1.83% | −0.93 |
| AKRO Akero Therapeutics Inc. | Reduce -32.9% | 7.35% | −0.75 |
| CGEM Cullinan Therapeutics Inc. | Reduce -6.4% | 2.51% | −0.12 |
Portfolio Buys Q1 2025 → Q2 2025
| RAPT Rapt Therapeutics Inc. | New | 7.03% | +7.03 |
| HNGE Hinge Health Inc. Class A | New | 3.93% | +3.93 |
| VSTM Verastem Inc. | New | 2.98% | +2.98 |
| XENE Xenon Pharmaceuticals Inc. | New | 2.82% | +2.82 |
| IDYA Ideaya Biosciences Inc. | New | 1.71% | +1.71 |
| CRVS Corvus Pharmaceuticals Inc. | Add +9.5% | 3.89% | +1.14 |
| RNAM Avidity Biosciences Inc. | New | 0.64% | +0.64 |
| SYRE Spyre Therapeutics Inc. | New | 0.59% | +0.59 |
| ALMS Alumis Inc. | Add +1.1% | 7.16% | −6.97 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $642.6M | CGON, ALMS, SPTX, DNLI, CLDX |
| Q1 2026 | 17 | $460.3M | CGON, ALMS, CNTA, CRVS, DNLI |
| Q4 2025 | 12 | $330.8M | CGON, RAPT, ALMS, CNTA, VSTM |
| Q3 2025 | 12 | $258.9M | CGON, RAPT, CNTA, VSTM, ALMS |
| Q2 2025 | 20 | $177.9M | CGON, CNTA, AKRO, ALMS, RAPT |
| Q1 2025 | 14 | $182.5M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, AKRO |
| Q4 2024 | 14 | $224.4M | CGON, ALMS, CNTA, RAPT THERAPEUTICS INC, BCAX |